Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis
Linagliptin treatment can attenuate the inflammatory response, protect against severe sepsis-induced vascular hyperpermeability, reduce multiorgan injury, and most importantly, improve the survival.
Authors
- Xinchun Lin (ORCID: https://orcid.org/0000-0001-5691-4782)
- Thomas Klein (ORCID: https://orcid.org/0000-0001-5762-9166)
- Christian T. Wohnhaas (ORCID: https://orcid.org/0000-0002-1450-9284)
- Jin-Rui Zhang
- Huiying Feng
- Dongmei Wu (ORCID: https://orcid.org/0000-0003-0380-7224)
- Denis Delić (ORCID: https://orcid.org/0000-0001-6798-3134)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Guangdong Pharmaceutical University (CN)
- Mount Sinai Medical Center (US)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1016/j.biopha.2024.117778
- Citations
- 7
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Boehringer Ingelheim